Loading viewer...
investor_presentation
Format: PDF investor_presentation
Skye Bioscience outlines its strategy to develop novel pharmaceutical products targeting the endocannabinoid system, with focus on CB1 receptor modulation. The presentation covers clinical development of product candidates including nimacimab and SBI-100 Ophthalmic Emulsion, addressing neuropathic, inflammatory, and metabolic diseases.
investor_presentation
50 Pages
iA Financial Group
Honeywell International Investor Presentation — September 2022
investor_presentationinvestor_presentation
10 Pages
Honeywell International Inc.